Receive our newsletter – data, insights and analysis delivered to you
June 29, 2009

Bayer Schering Signs Cancer Therapeutics Agreement with Celera

Bayer Schering Pharmaceuticals has signed a license agreement with Celera to gain access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging. Bayer Schering will pay Celera a one-time fee for exclusive access to the five targets as well as additiona

By cms admin

Bayer Schering Pharmaceuticals has signed a license agreement with Celera to gain access to five cancer-related targets for therapeutic development and in-vivo diagnostic imaging.

Bayer Schering will pay Celera a one-time fee for exclusive access to the five targets as well as additional payments on achievement of certain development and commercial milestones. Celera will then be entitled to royalties based on sales of the product.

Celera vice-president of proteomic research Steve Ruben said that the deal would combine the strength of Celera’s proteomics target discovery platform with Bayer Schering Pharma’s expertise in research and development.

“We believe this new relationship with Bayer Schering Pharma allows us the flexibility to advance part of our broad pipeline of validated targets for additional future value,” Ruben said.

Bayer Schering head of target discovery Professor Khusru Asadullah said that the agreement would allow for expansion within the current portfolio in the area of cancer-related targets.

“We look forward to exploring the full potential of these promising target candidates with regards to therapeutic interference for anti-tumour therapy as well as in-vivo diagnostic imaging,” Asadullah said.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU